GlassScriptPhysician profile
Mara Hummel
NPI 1477125904
$1,006.15
in general payments reported to CMS, 2019-2025
17 companies · $398 in 2025
The $398 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $77.28 · 2022: $185 · 2023: $177 · 2024: $169 · 2025: $398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.45 |
| Education | $289.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $190.96 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.65 | 2022-2023 | |
| Pfizer INC. | $120.44 | 2025 | |
| Seagen INC. | $99.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $95.33 | 2025 | |
| Abbvie INC. | $90.07 | 2024-2025 | |
| Amgen INC. | $57.49 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $54.84 | 2023 | Imbruvica, Epkinly |
| Celgene Corporation | $33.13 | 2022-2024 | Reblozyl |
| Genzyme Corporation | $22.65 | 2022 | |
| Coherus Oncology, INC. | $19.79 | 2021 | |
| Beigene USA, INC. | $19.44 | 2022 | |
| Genmab U.S., INC. | $17.59 | 2024 | Tivdak |
| Glaxosmithkline, LLC. | $17.04 | 2025 | Blenrep |
| Merck Sharp & Dohme LLC | $17.03 | 2025 | Keytruda |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $16.74 | 2022 | |
| Rigel Pharmaceuticals, INC. | $9.96 | 2023 | Tavalisse, Rezlidhia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mara Hummel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.